You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim

Last Updated: September 30, 2023

Details for Patent: 6,469,009

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,469,009
Title: Pharmaceutical compositions for the treatment of rhinitis
Abstract:A pharmaceutical composition comprising a therapeutically effective amount of a mixture consisting essentially of (i) pseudoephedrine, an individual optical isomer or a pharmaceutically acceptable salt thereof, and (ii) at least one compound selected from 2-[4-(diphenylmethyl)-1-piperazinyl]-acetic acid or amide derivatives, an individual optical isomer or a pharmaceutically acceptable salt thereof.
Inventor(s): Van De Venne; Herman (Lasne, BE), Martin; Jean-Pierre (Montigny-le-Tilleul, BE)
Assignee: UCB, S.A. (Brussels, BE)
Application Number:08/629,144
Patent Claim Types:
see list of patent claims
Composition; Compound; Use; Dosage form;

Drugs Protected by US Patent 6,469,009

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 6,469,009

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 1774097 ⤷  Try a Trial
Australia 723364 ⤷  Try a Trial
Brazil 9701686 ⤷  Try a Trial
Colombia 4820432 ⤷  Try a Trial
United Kingdom 2311940 ⤷  Try a Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.